HOME >> MEDICINE >> NEWS
Sandia-developed foam likely would stop SARS virus quickly, Sandia/Kansas State team shows

ormulations against BCV using cell culture methods with and without organic material present. Organic materials such as soil and feces may improve the survival rate of coronaviruses and can react directly with the disinfectant to make it less effective.

They also used diluted concentrations of the formulation, down to 10 percent of normal, and altered recipes of the formulation with similar results.

"We didn't want to test the formulations in the best-case scenario," says Cecelia Williams of Sandia. "We wanted the worst-case scenario to provide a margin of certainty that this would inactivate the SARS-causing virus under real-world conditions."

The lower concentration makes the formulation, already much less corrosive and toxic than other decontamination products such as bleach or ammonia, even more benign, she says.

Currently no disinfectant products are registered with the Environmental Protection Agency (EPA) specifically for killing the SARS virus on surfaces.

Two commercially available versions of the Sandia formulation also were effective in inactivating the virus in the tests, she says.

New protocols for viral inactivation

A second significant outcome of the joint research is a set of protocols and a methodology to verify viral inactivation. A SARS workshop in October 2003 sponsored by the World Health Organization identified the standardization of test protocols as one urgent need in responding to future SARS outbreaks.

Currently very little information is available in the scientific literature regarding chemical inactivation of viruses, says team member Jill Bieker, a Sandia intern currently working on a PhD at K-State. The work at K-State was conducted under the guidance of Dr. Sanjay Kapil, a world-renowned coronavirus expert.

As part of the project, Sandia conducted experiments to develop methods of applying the formulation and to determine how inactivation can be measured and
'"/>

Contact: John German
jdgerma@sandia.gov
505-844-5199
DOE/Sandia National Laboratories
2-Feb-2004


Page: 1 2 3 4

Related medicine news :

1. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
2. Blacks less likely to get expensive, newer heart treatments
3. Women less likely to get quality heart attack care
4. English-speaking Hispanic youth more likely to have sex early
5. Men more likely to get screened for prostate cancer than colon cancer, U-M study finds
6. A safer route to school makes children more likely to walk and bike, study shows
7. Hyperactive kids three times as likely to be removed from their families
8. Older doctors less likely to follow current standards of care
9. Alcohol drinkers three times as likely to die from injury
10. New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding
11. Hospital admissions for asthma more likely for ethnic minorities in the UK

Post Your Comments:
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: